Insider Buying: AstraZeneca plc (AZN) Insider Buys 8,500 Shares of Stock

Insider Buying: AstraZeneca plc (AZN) Insider Buys 8,500 Shares of Stock

AstraZeneca plc (LON:AZN) insider Marc Dunoyer acquired 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average cost of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82).

AZN stock opened at GBX 5,835 ($76.24) on Thursday. AstraZeneca plc has a 12-month low of GBX 5,110 ($66.77) and a 12-month high of GBX 6,540 ($85.46). The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 179.66. The stock has a market cap of $76.54 billion and a price-to-earnings ratio of 30.71.

A number of equities research analysts have recently commented on AZN shares. Barclays lifted their price objective on AstraZeneca from GBX 6,800 ($88.85) to GBX 7,000 ($91.47) and gave the company an “overweight” rating in a research report on Monday, April 1st. Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca and gave the company a “sell” rating in a research report on Thursday, April 11th. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Wednesday, March 20th. UBS Group reaffirmed a “sell” rating and issued a GBX 5,400 ($70.56) price objective on shares of AstraZeneca in a research report on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price objective on AstraZeneca and gave the company a “buy” rating in a research report on Tuesday, January 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 6,367.70 ($83.21).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Put Option

Related posts

Leave a Comment